Forward Pharma A/S announced that it has appointed Jan van de Winkel, Ph.D, President and Chief Executive Officer of Genmab, to its Board of Directors, effective immediately. Dr. van de Winkel is a co-founder of Genmab and currently serves as President and Chief Executive Officer. He has more than 20 years of experience in the therapeutic antibody field, is the author of over 300 scientific publications and has been responsible for more than 40 patents and pending patent applications.

He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals and Celdara Medical. Prior to Genmab, Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe.